Relationship between the expression of O6-methylguanine-DNA methyltransferase in glioma and the survival time of patients

• Published in: Ai zheng = Aizheng = Chinese journal of cancer Vol. 23; no. 9; p. 1052
• Main Authors: Sun, Yan-Hui, Zhang, Ya-Zhuo, Wang, Zhong-Cheng, Sun, Mei-Zhen, Zhao, Dong-Hai
• Format: Journal Article
• Language: Chinese
• Published: China 01.09.2004
• Subjects: Adolescent; Adult; Aged; Astrocytoma - metabolism; Astrocytoma - mortality; Brain Neoplasms - metabolism; Brain Neoplasms - mortality; Child; Child, Preschool; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Glioblastoma - metabolism; Glioblastoma - mortality; Glioma - metabolism; Glioma - mortality; Humans; Male; Middle Aged; O-Methylguanine-DNA Methyltransferase - metabolism; Oligodendroglioma - metabolism; Oligodendroglioma - mortality; Survival Rate

Previous studies showed that the DNA-repair enzyme O(6)-methylguanine-DNA methyltransferase (MGMT) is one of drug resistant factors that affect chemosensibility of glioma. This study was to analyze the relationship between the expression of MGMT in glioma and the survival time of patients,and supply references to make molecular classification for glioma based on drug resistant mechanism. MGMT expression in 311 glioma specimens was examined by tissue array technology and immunohistochemistry method, all patients had been followed up for 5 years, and the materials were analyzed statistically. The positive expression of MGMT was 126 in 311 gliomas (40.51%), among them, 61 in 121 astrocytomas (50.41%), 18 in 70 oligodendrogliomas (25.71%), 18 in 64 oligoastrocytomas (28.13%), 29 in 56 glioblastomas (51.79%); 68 in 186 grade I-II gliomas (36.56%), and 58 in 125 grade III-IV gliomas (46.40%). The difference of MGMT expression between grade I-II and grade III-IV gliomas was significant (P< 0.001). According to Kapla